Skip to content
Subscriber Only

Mylan to Add Abbott’s Generic-Drug Unit for Tax Advantage

Mylan Inc. is buying Abbott Laboratories’ generic drug business in established markets like Europe and forming a new company that will be incorporated in the Netherlands, cutting its taxes.

Abbott will get 21 percent of the new organization, a share valued at about $5.3 billion, the Abbott Park, Illinois-based company said today in a statement. Setting up in the Netherlands will drop Mylan’s tax rate to less than 21 percent in the first year, subsequently declining to the high teens. The company will be run by Mylan’s executive team from Pittsburgh, where Mylan’s headquarters are now.